Formulary assessment – Glucagon (Ogluo)

Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.

The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.

This information is produced for use by NHS healthcare professionals and RDTC stakeholders.

Comparison of DPP-4 inhibitors (Gliptins)

Comparison documents are designed to support prescribers and medicines management teams to maximise health gains through the optimum use of medicines within a specific therapeutic area.

There are currently five dipeptidyl peptidase-4 (DPP-4) inhibitors (or gliptins) available in the UK for the management of type 2 diabetes mellitus. There are a number of differences between the DPP-4 inhibitors in terms of licensing, interactions, renal impairment dose adjustment, hepatic impairment dose adjustment, and cost. This comparison table allows prescribers and other healthcare professionals to easily compare the characteristics of these medicines.

Formulary assessment – metolazone (Xaqua)

Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.

The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.

This information is produced for use by NHS healthcare professionals and RDTC stakeholders.

Optimising the use of morphine 10mg/5mL oral solution in primary care (Update)

Overview

Medicines in Practice is a series of evidence–based publications specifically designed to support stakeholder medicines optimisation services. The series aims to maximise health gains through the optimum use of medicines, by influencing and changing prescribing behaviour.

Opioids are effective for acute pain and pain at the end of life, but there is little evidence of their effectiveness for long term pain. This document supports primary care teams to review patients receiving regular large quantities of morphine 10mg/5mL oral solution and includes advice on how these patients could be managed.

This publication was updated in September 2022 to include opioid equivalence information to align with the updated Opioids Aware information, and information on safety issues identified with morphine oral solution 10mg/5mL. This update also highlights the availability of the NHSBSA opioid dashboard which can be used to identify patients for review.

Download the full review below to read more.

Monthly Horizon Scanning Report – September 2022

Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies. 

This information is produced for use by NHS healthcare professionals. 

Top 50 BNF sections and drugs

Overview

This report looks at the top 50 BNF sections and drugs in terms of spend at SICBL level for the financial year to date with a focus on cost growth and item growth.

Frequency

Quarterly

Data period

April 2022 to September 2022

Monthly Financial Headlines

Overview

This report monitors budget performance based on total prescribing for the whole BNF at sub-ICB and PCN level for the financial year to date with particular focus on cost and item growth compared to the same period from the previous financial year.

Frequency

Monthly

Data period

September 2022

Prescribing Update Newsletter – September 2021

Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.

If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net

This month’s edition covers the RDTC’s Climate Emergency declaration, Pill Swallowing – a skill for life, Metolazone preparations and safety considerations, and the second in the series of “Meet the Team” where you can get to know the people behind the work we do. We also cover the Price concessions and the Discount Deduction scheme, World Antimicrobial Awareness Week, and a guide to the COVID-19 autumn booster. There is also information on the changes to the Medicines Information Service, and some key medicines availability issues.

This month’s edition covers new labelling requirements for sennosides, changes to the NHS community pharmacy contract, National guidance on blood testing following shortages, and inclisiran in primary care. It also continues a series of spotlight articles on our prescribing data reports; this month takes a look at our prescribing bulletins.

North of England Integrated Care Systems; Overprescribing

This bulletin provides an update on key primary care prescribing trends in the North of England, which relate to ‘Overprescribing’; incorporating ‘Polypharmacy’. It provides a snapshot of overprescribing in the North of England Integrated Care Systems, including the percentage of patients receiving five or more unique analgesic medicines, and those receiving three unique medicines (not licensed for hypertension) with a hypotensive side effect.

A supplementary appendices containing the respective CCG level data is also available to download

Reducing the carbon impact of inhalers across the North of England

This bulletin provides baseline figures on the current Inhaler Carbon Footprint at ICS level in the North of England, in order that systems can identify the level of response to be undertaken. It examines the current carbon footprint attributed to Inhalers in the North East and Yorkshire and the North West. It also analyses the Inhaler carbon footprint by therapeutic class, Inhaler type, and the contribution of hospital admissions for asthma towards total Inhaler carbon footprint.